• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·3613.HK
Share

Beijing Tong Ren Tang Chinese Medicine Company Limited Stocks

HK$ 6.36Last Updated 25.06.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

HK$ 697.60M

HK$ 6.36
Key Takeaways

Risk factor

Modest price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Tong Ren Tang Chinese Medicine Company Limited, encompassing its various affiliates, specializes in the production, distribution, and direct sale of traditional Chinese medicine and wellness items, catering to both corporate distributors and individual consumers. Its operations are geographically segmented across Hong Kong, Mainland China, and international markets. Additionally, the company provides traditional Chinese medical consultations and therapeutic services. The firm maintains a network of 23 retail stores throughout Hong Kong, complemented by 46 international outlets located across Asia, Oceania, North America, and Europe. All its offerings are sold under the well-recognized Tong Ren Tang brand. Established in 1669, the company's main office is situated in Wan Chai, Hong Kong.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, 'cheap'

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 3613.HK is 10 and suggests 60.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.06.2026 03:02

Bain has revised its forecast for luxury market growth downward. Why is it talking about a recovery in the industry?

26.06.2026 01:29

Market Split: Nasdaq Falls for the Fourth Consecutive Day Despite a Rally in Chipmakers

26.06.2026 00:48

Qualcomm will produce AI chips for Meta's data centers. Its stock soared

26.06.2026 00:13

Citigroup raised its price target for SanDisk by 23%. Its stock has already risen 860% in 2026

25.06.2026 23:22

Iran Attacked a Cargo Ship in the Strait of Hormuz — WSJ. Oil Prices Rise

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026